| Gene name: | PTGES2 |
| Aging type: | Accelerate |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | HUVEC |
| Experiment: | SA-β-gal activity assay//Immunofluorescence |
| Description: | Starting from 2 days after the beginning of the treatment, PGE2 had a marked effect on growth inhibition, only in the presence of a high concentration of glucose.In accordance, we observed a statistically significant increase in the percentage of cells expressing the cell-cycle inhibitor p16, only in the presence of a high concentration of glucose. PGE2 also induced an increase in the number of SA-β-Galpositive cells, again only in the presence of a high concentration of glucose .It is worth to note that the growth, the p16 expression, and the SA-β-Gal staining were not affected by the supplementation in glucose perse. |
| Target gene: | EP3 |
| Official symbol(s): | PTGER3 |
| R-AG-Target gene: | -- |
| Subcategory: | Unclear |
| Target gene experiment: | SA-β-gal activity assay |
| Target gene description: | The EP3 antagonist led to a statistically significant decrease of SA-β-Gal activity.We treated NHDFs with an agonist of EP3 (sulprostone) and found that it increased the number of SA-β-Gal-positive cells at the same level of that induced by PGE2. |
| Regulatory pathway: | -- |
| R-AG-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation:
Loading,please wait...